Phase 2 N=208 Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=445 Platelet Count Trends in Pre-eclamptic Parturients
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Phase 3 N=10,154 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
Preeclampsia
Primary: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate — 305; 285 Participants — p=0.42
Phase 3 N=2,464 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention
Pregnancy Complications · Preeclampsia
Primary: Preeclampsia — 169; 156 Participants — p=0.37
Early Phase 1 N=11 Losartan for Improved Vascular Endothelial Function After Preeclampsia
Preeclampsia Postpartum
Primary: Cutaneous Conductance (%Maximum) Response to Acetylcholine — 89.4; 72.5 % of maximal cutaneous conductance
N/A N=46 Restrictive Fluid Therapy in Severe Preeclampsia
Pre-Eclampsia
Primary: Renal Function in Severe Preeclampsia With Restrictive Fluid Therapy — 0.69; 0.73; 0.99; 0.93 mg/dl — p=<0.05
Phase 4 N=100 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
Pre-Eclampsia · HELLP Syndrome · Eclampsia
Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
N/A N=151 Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
Cardiovascular Disease · Preeclampsia · Hypertension
Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale
Phase 3 N=220 Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Pre-Eclampsia · Hypertension in Pregnancy · Obesity
Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants
Early Phase 1 N=23 Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
Phase 1 N=10 Phase I Study of Nicotinamide for Early Onset Preeclampsia
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Phase 4 N=110 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
Preeclampsia Severe
Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants
N/A N=110 Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
Preeclampsia · Hypotension
Primary: The Umbilical Artery pH — 7.22; 7.20 pH — p=.38
Phase 3 N=120 Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Preeclampsia
Primary: Increase in Gestational Age in Days — 5.0; 6.0 days